Everest Medicines

News

06 2022/04

Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis
31 2022/03

Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
30 2022/03

Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
29 2022/03

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2021
26 2022/03

Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients
15 2022/03

Everest Medicines to Announce Full-Year 2021 Financial Results on March 29, 2022
14 2022/03

Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea
12 2022/03

Everest Medicines Announces that Licensing Partner Gilead Sciences' Phase 3 TROPiCS-02 Study Meets Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer
10 2022/03

Everest Medicines Announces that Licensing Partner Venatorx Pharmaceuticals Reports Positive Results from Pivotal Phase 3 Cefepime-Taniborbactam Trial
07 2022/02

Everest Medicines Announces First Drug Approval of Trodelvy^® in Singapore for Second-Line Metastatic Triple-Negative Breast Cancer
14 2022/01

Everest Medicines Enters into a Global Licensing Agreement to Develop and Commercialize Singapore’s Experimental Drug Development Centre’s 3CL Protease Inhibitors as Potentially Best-in-Class COVID-19 Oral Antiviral Treatments Worldwide
10 2022/01

Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy^® in Combination with KEYTRUDA^® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer

Copyright Everest Medicines 2020 云顶药业（苏州）有限公司苏ICP备20038571号 | Terms of Use | Privacy Policy | Disclaimers

沪公网安备 31010602006477号